Follicular Lymphoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 291 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Follicular Lymphoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H2 2014', provides an overview of the Follicular Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Follicular Lymphoma Overview 8
Therapeutics Development 9
Pipeline Products for Follicular Lymphoma - Overview 9
Pipeline Products for Follicular Lymphoma - Comparative Analysis 10
Follicular Lymphoma - Therapeutics under Development by Companies 11
Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 14
Follicular Lymphoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Follicular Lymphoma - Products under Development by Companies 18
Follicular Lymphoma - Products under Investigation by Universities/Institutes 20
Follicular Lymphoma - Companies Involved in Therapeutics Development 21
Bristol-Myers Squibb Company 21
Johnson & Johnson 22
Boehringer Ingelheim GmbH 23
F. Hoffmann-La Roche Ltd. 24
Amgen Inc. 25
GlaxoSmithKline plc 26
Genentech, Inc. 27
MedImmune, LLC 28
Gilead Sciences, Inc. 29
Merck & Co., Inc. 30
Infinity Pharmaceuticals, Inc. 31
Celltrion, Inc. 32
Millennium Pharmaceuticals, Inc. 33
Novartis AG 34
Biocon Limited 35
ImmunoGen, Inc. 36
Ono Pharmaceutical Co., Ltd. 37
Genmab A/S 38
Sandoz Inc. 39
Celgene Corporation 40
Bayer AG 41
Immunomedics, Inc. 42
Accentia Biopharmaceuticals, Inc. 43
Pharmacyclics, Inc. 44
Affimed Therapeutics AG 45
Memgen, LLC. 46
ProNAi Therapeutics, Inc. 47
AmpliMed Corporation 48
CureTech Ltd. 49
Biothera, Inc. 50
Karyopharm Therapeutics, Inc. 51
MENTRIK Biotech, LLC 52
Rhizen Pharmaceuticals SA 53
AbbVie Inc. 54
Mirati Therapeutics Inc. 55
Follicular Lymphoma - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 61
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
bortezomib - Drug Profile 69
ibrutinib - Drug Profile 74
dasiprotimut-T - Drug Profile 79
lenalidomide - Drug Profile 81
ofatumumab - Drug Profile 84
ocaratuzumab - Drug Profile 88
rituximab biosimilar - Drug Profile 90
rituximab biosimilar - Drug Profile 92
ixazomib citrate - Drug Profile 93
mocetinostat - Drug Profile 95
abexinostat hydrochloride - Drug Profile 98
idelalisib - Drug Profile 100
ISF-35 - Drug Profile 102
imexon - Drug Profile 104
pidilizumab - Drug Profile 106
epratuzumab - Drug Profile 108
tisagenlecleucel-T - Drug Profile 113
vorinostat - Drug Profile 115
buparlisib hydrochloride - Drug Profile 118
luminespib - Drug Profile 121
nivolumab - Drug Profile 124
PNT-2258 - Drug Profile 128
duvelisib - Drug Profile 130
pinatuzumab vedotin - Drug Profile 132
polatuzumab vedotin - Drug Profile 134
Imprime PGG - Drug Profile 136
GS-9973 - Drug Profile 140
moxetumomab pasudotox - Drug Profile 141
BVX-20 - Drug Profile 143
PRT-2070 - Drug Profile 144
DNA Fusion Vaccines - Drug Profile 145
obinutuzumab - Drug Profile 146
blinatumomab - Drug Profile 148
ulocuplumab - Drug Profile 151
GM-K562 Cell Vaccine - Drug Profile 152
AFM-11 - Drug Profile 154
Autologous Recombinant Idiotypic Vaccine - Drug Profile 155
copanlisib - Drug Profile 156
NSC-678515 - Drug Profile 159
IMGN-529 - Drug Profile 160
venetoclax - Drug Profile 161
rituximab biosimilar - Drug Profile 163
selinexor - Drug Profile 164
rituximab biosimilar - Drug Profile 166
TGR-1202 - Drug Profile 167
GSK-2816126 - Drug Profile 168
daratumumab - Drug Profile 169
interferon alfa-2b - Drug Profile 172
rituximab biosimilar - Drug Profile 173
SH-7129 - Drug Profile 174
ABT-737 - Drug Profile 176
Follicular Lymphoma - Recent Pipeline Updates 178
Follicular Lymphoma - Dormant Projects 273
Follicular Lymphoma - Discontinued Products 274
Follicular Lymphoma - Product Development Milestones 275
Featured News & Press Releases 275
Appendix 286
Methodology 286
Coverage 286
Secondary Research 286
Primary Research 286
Expert Panel Validation 286
Contact Us 287
Disclaimer 287

List of Tables
Number of Products under Development for Follicular Lymphoma, H2 2014 13
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Development by Companies, H2 2014 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Late Stage Development, H2 2014 19
Comparative Analysis by Clinical Stage Development, H2 2014 20
Comparative Analysis by Early Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Development by Companies, H2 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2014 24
Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 25
Follicular Lymphoma - Pipeline by Johnson & Johnson, H2 2014 26
Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 27
Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 28
Follicular Lymphoma - Pipeline by Amgen Inc., H2 2014 29
Follicular Lymphoma - Pipeline by GlaxoSmithKline plc, H2 2014 30
Follicular Lymphoma - Pipeline by Genentech, Inc., H2 2014 31
Follicular Lymphoma - Pipeline by MedImmune, LLC., H2 2014 32
Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2014 33
Follicular Lymphoma - Pipeline by Merck & Co., Inc., H2 2014 34
Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2014 35
Follicular Lymphoma - Pipeline by Celltrion, Inc., H2 2014 36
Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 37
Follicular Lymphoma - Pipeline by Novartis AG, H2 2014 38
Follicular Lymphoma - Pipeline by Biocon Limited., H2 2014 39
Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H2 2014 40
Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 41
Follicular Lymphoma - Pipeline by Genmab A/S, H2 2014 42
Follicular Lymphoma - Pipeline by Sandoz Inc., H2 2014 43
Follicular Lymphoma - Pipeline by Celgene Corporation, H2 2014 44
Follicular Lymphoma - Pipeline by Bayer AG, H2 2014 45
Follicular Lymphoma - Pipeline by Immunomedics, Inc., H2 2014 46
Follicular Lymphoma - Pipeline by Accentia Biopharmaceuticals, Inc., H2 2014 47
Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2014 48
Follicular Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2014 49
Follicular Lymphoma - Pipeline by Memgen, LLC., H2 2014 50
Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2014 51
Follicular Lymphoma - Pipeline by AmpliMed Corporation, H2 2014 52
Follicular Lymphoma - Pipeline by CureTech Ltd., H2 2014 53
Follicular Lymphoma - Pipeline by Biothera, Inc., H2 2014 54
Follicular Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 55
Follicular Lymphoma - Pipeline by MENTRIK Biotech, LLC, H2 2014 56
Follicular Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2014 57
Follicular Lymphoma - Pipeline by AbbVie Inc., H2 2014 58
Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2014 59
Assessment by Monotherapy Products, H2 2014 60
Number of Products by Stage and Target, H2 2014 63
Number of Products by Stage and Mechanism of Action, H2 2014 67
Number of Products by Stage and Route of Administration, H2 2014 70
Number of Products by Stage and Molecule Type, H2 2014 72
Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H2 2014 182
Follicular Lymphoma - Dormant Projects, H2 2014 277
Follicular Lymphoma - Discontinued Products, H2 2014 278